6/9/25 We are currently making changes to reflect the new Health Sciences Division structure. Thank you for your patience.

Sign in
Stratified glucose-lowering response to vildagliptin and pioglitazone by obesity and hypertriglyceridemia in a randomized crossover trial
Journal article   Open access   Peer reviewed

Stratified glucose-lowering response to vildagliptin and pioglitazone by obesity and hypertriglyceridemia in a randomized crossover trial

Rebecca Brandon, Yannan Jiang, Rui Qian Yeu, Ry Tweedie-Cullen, Kate Smallman, Glenn Doherty, Kerry A Macaskill-Smith, Rebekah J Doran, Penny Clark, Allan Moffitt, …
Frontiers in endocrinology (Lausanne), Vol.13, pp.1091421-1091421
09/01/2023
Handle:
https://hdl.handle.net/10523/17350

Abstract

Adult Cross-Over Studies Diabetes Mellitus, Type 2 - drug therapy Dipeptidyl-Peptidase IV Inhibitors - therapeutic use Glucose - therapeutic use Glycated Hemoglobin Humans Hypertriglyceridemia - drug therapy Hypoglycemic Agents - therapeutic use Nitriles - therapeutic use Obesity - complications Obesity - drug therapy Pioglitazone - therapeutic use Pyrrolidines - therapeutic use Thiazolidinediones - therapeutic use Vildagliptin - therapeutic use
url
https://doi.org/10.3389/fendo.2022.1091421View
Published (Version of record) Open

Details

Logo image